EN DE
Watch Mabpharm Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mabpharm Ltd (2181) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Mabpharm Ltd stock HK$0.13, price HK$0.49, that is 73.5% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG5780F1046

ML Mabpharm Ltd logo Thin data Nov 14, 2026

Mabpharm Ltd

2181 · HK

Far too expensive (fair value 74% below the price) and price moving sideways, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Solidly profitable · 11.1% net margin (TTM) 
Low debt 
Generates free cash flow over the last twelve months 
Ranks above peers (8/12) 
Revenue last quarter +45% vs. a year ago. 
Quality 55/100 
Price moving sideways (no uptrend) 
Mixed Growth (revenue 3y +124.1 %/yr in CNY) 
Moderate moat 56/100 · thin data
Fair value HK$0.1300 · Strongly overvalued 
Thin data 
Watch Mabpharm Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$1.31 HK$0.2500 Fair Value HK$0.1300 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range HK$0.2500 – HK$1.31 · fair‑value band HK$0.0700 – HK$0.2300 · the HK$0.4900 price screens above the HK$0.1300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Mabpharm in your weekly email

Every Wednesday you see whether Mabpharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People's Republic of China.

Show moreShow less

It offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment of ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, Crohn's disease in adults and pediatric patients aged above 6 years old, fistula Crohn's disease, and psoriasis.

The company also develops CMAB807/CMAB807X that has completed Phase III clinical trial for the treatment of osteoporosis, tumor bone metastasis, and giant-cell tumor of bone; CMAB819 that has completed Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis that is in Phase I clinical trial.

In addition, its products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB016, a biosimilar product candidate of dupilumab for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), and prurigo nodularis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab.

Further, the company is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, chemical biological reagents, diagnostic reagents, and drugs.

Mabpharm Limited was incorporated in 2018 and is headquartered in Taizhou, China.

Stock analysis

Mabpharm Ltd (2181) currently trades at HK$0.4900, while our model-based Fair Value estimate is HK$0.1300, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$0.7400 per share, and 4 of the 13 models we run sit above the HK$0.4900 price.

Bear case: the Economic Profit group reads lowest at HK$0.0750, and 9 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.0700 (bear) to HK$0.2300 (bull), the price of HK$0.4900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Mabpharm Ltd reported revenue of 629M CNY in FY2025 versus 82.9M CNY in FY2021, a compound +66.0%/yr. Reported net income was 55.7M CNY in FY2025.

Key figures

Market cap HK$2.0B (≈ $258M) Micro · P/E ratio 21.8 · P/S ratio 1.92 · Net margin 8.8% · Return on equity 58.5% · Return on assets (EBIT) −17.7% (5-year average) · Operating margin 8.5% · Revenue (TTM) 770M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −74%, 2181 screens richer than that median.

Fair Value models

Bear HK$0.0700 Fair Value HK$0.1300 Bull HK$0.2300
Price HK$0.4900 · Downside -73.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV HK$0.0200 HK$0.0200 HK$0.0200 74
Owner Earnings HK$0.0700 HK$0.1300 HK$0.2300 71
ROIC Compounder HK$0.0200 HK$0.0200 HK$0.0200 70
All 13 models by family
DCF Models
Owner Earnings HK$0.0700 HK$0.1300 HK$0.2300 71
Earnings-Based
Graham-Dodd HK$0.1100 HK$0.7500 HK$1.05 61
Lynch FV HK$0.3900 HK$0.5500 HK$0.7200 59
PEG = 1.0 HK$0.3900 HK$0.5500 HK$0.7200 55
EPV HK$0.0200 HK$0.0200 HK$0.0200 74
Multiples
P/E Multiple HK$0.2600 HK$0.3500 HK$0.4400 63
P/S Multiple HK$0.2000 HK$0.2700 HK$0.3400 58
P/B Multiple HK$0.0600 HK$0.0800 HK$0.1000 55
EV/EBITDA HK$0.1300 HK$0.2000 HK$0.2600 66
Asset-Based
NCAV (Graham) HK$0.0100 HK$0.0100 HK$0.0200 52
Economic Profit
Residual Income HK$0.0800 HK$0.1300 HK$0.2800 62
ROIC Compounder HK$0.0200 HK$0.0200 HK$0.0200 70
Growth Earnings
Growth-Adj P/E HK$0.5200 HK$0.7400 HK$0.9600 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 60
How much profit the company makes from its sales and capital
Quality Growth 86
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 11
Debt, balance sheet and risk of trouble
Investment 60
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 44
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 30
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+143.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+124.1%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,384.4% (2019) → 0.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

2181 screens overvalued: fair value 74% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Mabpharm Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 55 · Top 25%
Fair Value upside −73.5% · Bottom 25%
Profitability
Return on equity (12 months) 58.5% · Top 25%
Return on assets 4.8% · Top 25%
Net margin (12 months) 11.1% · Above median
Operating margin (12 months) 8.5% · Above median
Growth and dividend
Revenue growth (quarter YoY) 45.1% · Top 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 21.8× · Cheaper than median
P/B 10.92× · Priciest 25%
P/S (12 months) 2.23× · Cheapest 25%
EV/EBITDA 18.6× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)79 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 2181
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 2181
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 2181
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs 2181
argenx SE ARGX $960.04 $908.40 −5% vs 2181
CSL Limited CSL A$202.52 A$185.51 −8% vs 2181
Moderna, Inc MRNA $223.37 $139.99 −37% vs 2181
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs 2181
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 2181
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 2181

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mabpharm Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mabpharm Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2181

Frequently asked questions

Is Mabpharm Ltd (2181) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$0.1300 versus a price of HK$0.4900, about 74% lower (overvalued).
What is the fair value of 2181?
Our model-based fair value for Mabpharm Ltd is HK$0.1300 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$0.4900.
What is the quality score of 2181?
Mabpharm Ltd has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mabpharm Ltd (2181)?
Our model-based price target is the fair value of HK$0.1300 (as of Nov 14, 2026) from 13 valuation models. Cautious scenario HK$0.0700, optimistic scenario HK$0.2300. It is a calculation from audited fundamentals, not an analyst target.
What is the Mabpharm Ltd stock forecast for 2026?
Our models put fair value at HK$0.1300, about 74% lower versus a price of HK$0.4900 (overvalued). Cautious scenario HK$0.0700, optimistic scenario HK$0.2300. The calculation is refreshed regularly with new filings.
What is the revenue of Mabpharm Ltd (2181)?
Mabpharm Ltd reported trailing-twelve-month revenue of about 770M CNY (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Mabpharm Ltd (2181)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mabpharm Ltd it is HK$0.1300 per share (as of Nov 14, 2026), against a price of HK$0.4900. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Mabpharm Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 2181 trades above its calculated fair value: price HK$0.4900, fair value HK$0.1300, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2181?
No. The price is what the market pays today (HK$0.4900); the fair value is what the company's own numbers justify (HK$0.1300). For Mabpharm Ltd the two are HK$0.3600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mabpharm Ltd worth?
The market values Mabpharm Ltd at about HK$2.0B (market capitalisation, as of Nov 14, 2026). Per share that is HK$0.4900; our models calculate a fair value of HK$0.1300 per share.
What do the bullish and bearish scenarios say about 2181?
Our models span a range for Mabpharm Ltd: cautious scenario HK$0.0700, base HK$0.1300, optimistic HK$0.2300 per share (as of Nov 14, 2026, price HK$0.4900). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2181?
Mabpharm Ltd trades at a price-to-earnings ratio of 21.8 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.1300 is built from several models across several years. Other multiples: P/B 10.9, P/S 2.2, EV/EBITDA 18.6.
How solid is the balance sheet of Mabpharm Ltd (2181)?
Balance-sheet figures for Mabpharm Ltd (as of Nov 14, 2026): return on equity 58.5%, debt of 0.42 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 2181 from its 52-week high?
Mabpharm Ltd trades at HK$0.4900, about 32% below its 52-week high of HK$0.7200 and 32% above the low of HK$0.3700 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1300 is for.
Which stocks are comparable to Mabpharm Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mabpharm Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price HK$0.4900, calculated fair value HK$0.1300 (−74%), Quality Score 55/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2181 calculated?
We run Mabpharm Ltd through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.1300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Mabpharm Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mabpharm Ltd (2181)?
The closing price on Nov 13, 2026 was HK$0.4900. Our model-based fair value is HK$0.1300, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mabpharm Ltd right now?
The price sits above even our optimistic bull case (HK$0.2300). The favourable scenario is already priced in. The model range is unusually wide (HK$0.0700 to HK$0.2300). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Mabpharm Ltd

How large is the market capitalisation of Mabpharm Ltd (2181)?
The market capitalisation of Mabpharm Ltd is HK$2.0B (≈ $258M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mabpharm Ltd (2181)?
The price-to-sales ratio of Mabpharm Ltd is 1.92 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Mabpharm Ltd (2181)?
The net margin of Mabpharm Ltd is 8.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mabpharm Ltd (2181)?
The return on equity (ROE) of Mabpharm Ltd is 58.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mabpharm Ltd (2181)?
On an EBIT basis the return on assets of Mabpharm Ltd is −17.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mabpharm Ltd (2181)?
The operating margin of Mabpharm Ltd is 8.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mabpharm Ltd (2181)?
Revenue at Mabpharm Ltd is growing 45.1% versus a year earlier (3y avg +124%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mabpharm Ltd (2181)?
Earnings per share at Mabpharm Ltd are growing 983% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mabpharm Ltd (2181) generate?
The free cash flow of Mabpharm Ltd is −23.2M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mabpharm Ltd (2181) carry?
The net debt of Mabpharm Ltd is 218M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Mabpharm Ltd in the live analysis

One click puts Mabpharm Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.